Insurers can't avoid covering weight-loss drugs forever

Opinion editor's note: Star Tribune Opinion publishes a mix of national and local commentaries online and in print each day. To contribute, click here.

•••

New data illustrating the health benefits of Novo Nordisk's obesity drug Wegovy puts insurers in the increasingly uncomfortable position of justifying their refusal to pay for the new class of injectable weight-loss treatments known as GLP1 drugs.

As a society, we seem stuck in an old narrative: that Wegovy and its rivals are merely "lifestyle products" that offer a cosmetic, but not societal, benefit. But a highly anticipated trial, which enrolled roughly 17,600 people with a history of cardiovascular disease, found that people who took Wegovy had 20% fewer heart attacks and strokes. It's the first time a study has demonstrated those types of benefits in a population without diabetes.

While private insurers will cover GLP1 drugs for people with diabetes, they have been slower to pay for their use in people with obesity. A 2022 survey found that just 22% of employers in the U.S. pay for weight-loss medicines. Some 45%, meanwhile, cover bariatric surgery, for which the longer term health benefits are well-established.

Concerns over costs are valid. The drugs, which must be taken continuously in order to keep the pounds off, are expensive. Meanwhile, those employers fear they won't be the beneficiaries of long-term savings if people move on to another job.

State Medicaid coverage, meanwhile, is spotty at best. And Congress has yet to open the door for Medicare to pay for any obesity medicines. The fear, of course, is that the large percentage of people on public insurance who would qualify for the drugs would be budget-busting.

One thing that would help the overall discussion about access is a better accounting of the potential costs and savings of these drugs. Estimates vary wildly based on the way they are calculated. For example, one analysis found that, depending on private insurers' coverage, Medicare would save between $175 billion and $245 billion in the first 10 years of covering weight-loss drugs. But another analysis was much less rosy. Covering these drugs could cost Medicare $268 billion a year — that's if every eligible person were to take them.

The true costs and benefits are likely somewhere between those extremes. A more nuanced analysis — based on emerging clinical and real-world data — could help guide both public and private insurers to map out the best approach for coverage.

These drugs work. People lose weight — enough of it to really matter for their health. We need to have more honest conversations about these medicines' value to society.